Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

In propensity score-matched cohorts of 121,046 hospitalized patients, those with RA and T2D had an ILD prevalence of 2.25%, ...

"I don't need to tell this audience how dreadful the cough of IPF is," Morice said, noting that 85% of patients with IPF experience chronic cough ... GSK, Merck, Nocion, Philips Pharma Group ...

CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to ...

Amgen today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with ...

“Unlike smallpox, whooping cough or ... than 5% become chronic carriers and one-fourth of these could possibly be in danger of life-threatening liver disease later in life. How safe is the Hepatitis B ...

That means if you have any concurrent problem like hypertension, chronic obstructive pulmonary disease ... tetanus and pertussis (whooping cough). My mom almost died from diphtheria at the age of 16.